Hepatocellular adenoma: Morphological and molecular variants and distinction from well-differentiated hepatocellular carcinoma

Pathology Case Reviews

Volumn 14, Issue 1, 2009, Pages 13-20

  Kahn, Melissa E ^a   French, Samuel ^b   Wang, Hanlin L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Focal nodular hyperplasia; Glycogen storage disease; Hepatocellular adenoma; Hepatocellular carcinoma; Liver adenomatosis

Indexed keywords

BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA;

ADENOMATOSIS; CANCER RISK; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; GLYCOGEN STORAGE DISEASE TYPE 1; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER TRANSPLANTATION; MALE; MALIGNANT TRANSFORMATION; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL HEPATECTOMY; PATHOLOGY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TUMOR VOLUME; ULTRASOUND;

EID: 68549085464     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/PCR.0b013e31819c4956     Document Type: Review

References (33)

1. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32:312-315.
2. Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1α gene inactivation: cosegregation between liver adenomatosis and diabetes pheno-types in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab. 2004;89:1476-1480.
3. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. JAMA. 1979;242:644-648.
4. Veteläinen R, Erdogan D, de Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int. 2008;28:499-508.
5. Reddy SK, Kishnani PS, Sullivan JA, et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol. 2007;47:658-663.
6. Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur JPediatr. 2002;161:S46-S49.
7. Micchelli ST, Vivekanandan P, Boitnott JK, et al. Malignant transformation of hepatic adenomas. Mod Pathol. 2008;21:491-497.
8. Franco LM, Krishnamurthy V, Bali D, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis. 2005; 28:153-162.
9. Wanless IR, Albrecht S, Bilbao J, et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol. 1989;2:456-462.
10. Paradis V, Benzekri A, Dargère D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology. 2004; 126:1323-1329.
11. Paradis V, Bièche I, Dargère D, et al. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology. 2003;124:651-659.
12. Guindi M. So-called telangiectatic focal nodular hyperplasia: a newly recognized variant of hepatic adenoma. Pathol Case Rev. 2007;12:154-159.
13. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46:521-527.
14. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology. 2005;128:1211-1218.
15. Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol. 2008;48: 163-170.
16. Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32:312-315.
17. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515-524.
18. Jeannot E, Poussin K, Chiche L, et al. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1α-mutated hepatocellular adenoma. Cancer Res. 2007;67:2611-2616.
19. Huang H, He X. Wnt/β-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008;20:119-125.
20. Thompson MD, Monga SP. WNT/βbeta-catenin signaling in liver health and disease. Hepatology. 2007;45:1298-1305.
21. Bioulac-Sage P, Blanc JF, Rebouissou S, et al. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol. 2007;13:2649-2654.
22. Chen YW, Jeng YM, Yeh SH, et al. p53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology. 2002;36:927-935.
23. Rebouissou S, Imbeaud S, Balabaud C, et al. HNF1α inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem. 2007;282:14437-14446.
24. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740-748.
25. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457:200-204.
26. Zhang MQ, Chen ZM, Wang HL. Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol. 2006;19:573-580.
27. Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol. 2002;15: 189-196.
28. Chen ZM, Crone KG, Watson MA, et al. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol. 2005;29:1600 -1608.
29. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132:1723-1728.
30. Coston WM, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohisto-chemistry. Am J Surg Pathol. 2008;32:433-444.
31. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011-1018.
32. Anatelli F, Chuang ST, Yang XJ, et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008;130:219-223.
33. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384:407-408.